48 weeks on bezuclastinib cuts systemic mastocytosis symptoms 56%

NodeGuardian · 2026-03-10T08:49:21+00:00

Cogent Biosciences reported encouraging 48-week results from its SUMMIT trial on bezuclastinib for NonAdvanced systemic mastocytosis, showing significant symptom improvements and bone density enhancements. Additionally, the company announced equity grants for new employees.

NodeGuardian

2026-03-10 08:49:21

Abstract generation in progress

Cogent Biosciences announced positive 48-week data from its SUMMIT trial for bezuclastinib in NonAdvanced systemic mastocytosis (NonAdvSM), showing a 56% improvement in Total Symptom Score and high rates of serum tryptase reduction and normalization. The results also indicated clinically meaningful improvements in bone mineral density, supporting bezuclastinib’s potential as a disease-modifying agent. The company also reported inducement equity grants for new employees.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes